Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

INSULIN GLULISINE (DNA ORIGIN)

All injection strengths: general benefit

Other products in the same Health Canada class (A10A, A10AB) — coverage varies; not interchangeable

  • Insulin zinc crystalline human biosynthetic rdna origin (Humulin Regular): general benefit
  • Insulin aspart (NovoRapid): general benefit, Limited Use 646
  • Insulin human biosynthetic (Novolin ge Toronto): general benefit
  • Insulin lispro (Humalog): general benefit, Limited Use 646
  • Human biosynthetic + insulin (Entuzity KwikPen): general benefit

Apidra · DIN 02279460 · 100U/mL · injection solution-10mL Vial

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
No interchangeable product listed in the Ontario extract
Apidra · DIN 02279460 Manufacturer: Sanofi Aventis Pharma; listing date 2009-08-18 Health Canada: Marketed since 2008-09-22 · brand APIDRA · ATC A10AB06 INSULIN GLULISINE · form Solution · route Subcutaneous · ingredients INSULIN GLULISINE (RECOMBINANT DNA ORIGIN) 100 UNIT/ML · company Sanofi-aventis canada inc · schedule Schedule d
Check this DIN again · Health Canada product record

Apidra: Formulary list price $28.7600/unit (unit not stated in source; not the patient's cost)

Ministry pays: $28.7600 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=76506 · Verify on the e-Formulary ↗ (DIN 02279460)

Source record
DIN 02279460: Apidra Raw flags: insOH=Y, sec3=Y Item: 682010029; group id 771; item number 1881; lccId None; manufacturer id SAV Source form: Inj Sol-10mL Vial; strength: 100U/mL Recorded listing: General benefit; diabetes medication flag Source prices (unrounded): $28.7600; ministry $28.7600 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02279460 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=76506 Therapeutic Notes (formulary) Note: For the treatment of patients with Type 1 diabetes mellitus. For the treatment of patients with Type 2 diabetes mellitus using insulin in an intensive regimen with 3 or more injections per day or an insulin pump. For the treatment of patients with Type 2 diabetes mellitus who are either experiencing recurrent hypoglycemia OR are unable to achieve adequate post-prandial glucose control while on less intensive regimen of regular insulin (1-2 injections per day).
Shortage status: resolved shortage (ended 2023-07-11); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02279460
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Other drugs in the same formulary class (68:20:10 Insulins (Rapid Acting)) and how they are covered

Matched class: 68:20:10 Insulins (Rapid Acting)

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: INSULIN (ZINC CRYSTALLINE) HUMAN BIOSYNTHETIC (RDNA ORIGIN), INSULIN HUMAN BIOSYNTHETIC, INSULIN INJECTION, HUMAN BIOSYNTHETIC Some products covered without a code (check the product listing): INSULIN ASPART, INSULIN LISPRO 68:20:10 Insulins (Rapid Acting)

INSULIN (ZINC CRYSTALLINE) HUMAN BIOSYNTHETIC (RDNA ORIGIN)

· 2 products · General benefit · strengths: 1000U/10mL, 100U/mL · Inj Sol-10mL Pk, Inj Sol-5x3mL Pk

INSULIN ASPART

· 5 products · Limited Use, codes 646 (1), General benefit (4) · strengths: 100U/mL · Inj Sol-10mL Pk, Inj Sol-10mL Vial Pk, Inj Sol-5x3mL Cart Pk, Inj Sol-5X3mL Pref Pen Pk, Inj Sol-5x3mL SoloSTAR Pref Pen Pk

INSULIN HUMAN BIOSYNTHETIC

· 2 products · General benefit · strengths: 1000U/10mL, 100U/mL · Inj Sol-10mL Pk, Inj Sol-5x3mL Pk

INSULIN LISPRO

· 5 products · Limited Use, codes 646 (1), General benefit (4) · strengths: 100U/mL, 200U/mL · Inj Sol-10mL Pk, Inj Sol-10mL Vial Pk, Inj Sol-5x3mL Cart Pk, Inj Sol-5x3mL SoloSTAR Pref Pen Pk, Inj Sol-Pref Pen 5x3mL Pk

INSULIN INJECTION, HUMAN BIOSYNTHETIC

· 1 products · General benefit · strengths: 500U/mL · Inj Sol-Pref Pen 2x3mL Pk Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 68:20:10
Full class listing Related classes: 68:20:02 Oral Anti-Diabetic Agents, 68:20:06 Incretin Mimetics, 68:20:12 Insulins (Intermediate Acting), 68:20:14 Insulins (Long Acting), 68:20:16 Insulins (Pre-Mixed) Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
1 INDICATIONS APIDRA [insulin glulisine injection (rDNA origin)] is a recombinant human insulin analogue indicated for: - the treatment of adult patients with diabetes mellitus where treatment with insulin is required. - the treatment of pediatric patients with type 1 diabetes mellitus who require a short acting insulin. There is insufficient clinical data on the use of APIDRA in children below the age of 6 years (see 7 WARNINGS AND PRECAUTIONS, Special Populations, Pediatrics). APIDRA has a more rapid onset of action and a shorter duration of action than regular human insulin. APIDRA should normally be used in regimens that include a longer-acting insulin or basal insulin analogue to maintain adequate glucose control (see 4 DOSAGE AND ADMINISTRATION). APIDRA can be used with oral hypoglycemic agents. 1.1 Pediatrics Pediatrics (<6 years of age): Based on the data submitted and reviewed by Health Canada, the safety and efficacy of APIDRA in pediatric patients has been established. Therefore, Health Canada has authorized an indication for pediatric use (see 7 WARNINGS AND PRECAUTIONS). APIDRA has not been studied in pediatric patients younger than 4 year… https://pdf.hres.ca/dpd_pm/00063799.PDF PM date: December 1, 2021 Source product: APIDRA; DIN 02279460; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.